Approval · Notice of Compliance 11317 · 2010
RANITIDINE TABLETS: Notice of Compliance 11317
Issued April 28, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11317
- Date
- April 28, 2010
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- Histamine H2-receptor antagonist
- Canadian reference product
- ZANTAC (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RANITIDINE TABLETS | 02350203 | Cancelled Pre Market |
| RANITIDINE TABLETS | 02350211 | Cancelled Pre Market |
Medicinal ingredients
- RANITIDINE HCL 150 MG per TAB
- RANITIDINE HCL 300 MG per TAB